Browsing: Sino Biopharmaceutical

Sino Biopharmaceutical Announces 2020 First Quarterly Results

By Marie JonesMay 28, 20200

Revenue was approximately RMB6.22 Billion; Profit Attributable to Owners of the Parent was approximately RMB862 Million Sino Biopharmaceutical Limited (“Sino…

HealthCare

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

By Marie JonesMay 26, 20200

Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new…

BioTech

Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting

By Marie JonesMay 19, 20200

Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development (“R&D”) driven pharmaceutical conglomerate in the PRC, has announced…

HealthCare

Sino Biopharm Announces 2019 Annual Results

By Marie JonesMarch 31, 20200

Revenue Climbs 16.0% to RMB24.23 billion Underlying Profit Up 10.2% to RMB3.13 billion; Achieves an outstanding R&D performance and obtains…

BioTech

Sino Biopharmaceutical Announces 2018 Third Quarterly Results

By Marie JonesNovember 26, 20180

Profit Attributable to the Group Increased by Approximately 29.9% to Approximately RMB 2,247,477,000 HONG KONG – (ACN Newswire) – Sino Biopharmaceutical…